Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600381's Gross Margin % is ranked worse than 73.06% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs SHSE:600381: 35.53
Qinghai Spring Medicinal Resources Technology Co had a gross margin of 36.84% for the quarter that ended in Mar. 2026 => Competition eroding margins
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Qinghai Spring Medicinal Resources Technology Co had a gross margin of 36.84% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Qinghai Spring Medicinal Resources Technology Co Gross Margin % Related Terms
Qinghai Spring Medicinal Resources Technology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qinghai Spring Medicinal Resources Technology Co Gross Margin % Chart
Qinghai Spring Medicinal Resources Technology Co Annual Data
SHSE:600381 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Qinghai Spring Medicinal Resources Technology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qinghai Spring Medicinal Resources Technology Co Gross Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) has a Gross Margin % of 36.84% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. This is near median its historical median of 35.56. Over the past decade, Qinghai Spring Medicinal Resources Technology Co's Gross Margin % has ranged from 19.10 to 61.21. According to the industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #689 out of 943 companies in the Drug Manufacturers industry, placing it in the top 73.1%.
Is Qinghai Spring Medicinal Resources Technology Co's Gross Margin % too high?
Qinghai Spring Medicinal Resources Technology Co's current Gross Margin % of 36.84% is near median its 10-year median of 35.56. Over the past 10 years, this metric has ranged from a low of 19.10 to a high of 61.21. The Drug Manufacturers industry median Gross Margin % is 48.54. Qinghai Spring Medicinal Resources Technology Co's value of 36.84% is 24.1% below this industry median. Based on the distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #689 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Qinghai Spring Medicinal Resources Technology Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qinghai Spring Medicinal Resources Technology Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #689 out of 943 companies for Gross Margin %. This places Qinghai Spring Medicinal Resources Technology Co in the lower half of its industry. The industry median Gross Margin % is 48.54. Qinghai Spring Medicinal Resources Technology Co's value of 36.84% is 24.1% below this benchmark. Historically, Qinghai Spring Medicinal Resources Technology Co's own Gross Margin % has ranged from 19.10 to 61.21 over the past decade. While the company's 10-year median is 35.56 vs. the industry median of 48.54, Qinghai Spring Medicinal Resources Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qinghai Spring Medicinal Resources Technology Co's current Gross Margin % of 36.84% is 24.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qinghai Spring Medicinal Resources Technology Co's current Gross Margin % is 36.84%, which is near median its own 10-year median of 35.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qinghai Spring Medicinal Resources Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥4.20 — trading 28.2% below its estimated fair value. The current Gross Margin % is 36.84%, which is near median its 10-year median of 35.56 and 24.1% below the Drug Manufacturers industry median of 48.54. Qinghai Spring Medicinal Resources Technology Co's overall GF Score™ is 68/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Qinghai Spring Medicinal Resources Technology Co (SHSE:600381), the current Gross Margin % is 36.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Overvalued in 2026?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co stock appears to be undervalued.
The current stock price of ¥4.20 is trading 28.2% below its estimated GF Value™ of ¥5.85.
GuruFocus considers Qinghai Spring Medicinal Resources Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:600381:
Gross Margin %: 36.84% (near median its 10-year median of 35.56)
GF Value™: ¥5.85 vs. price of ¥4.20 (28.2% below fair value)
Industry Position: 24.1% below the Drug Manufacturers median (#689 of 943)
No single metric tells the full story. See the SHSE:600381 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qinghai Spring Medicinal Resources Technology Co Business Description
Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company that principally engaged in the integrated development, utilization, production, sales, and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company's main products are the cordyceps sinensis series products under the Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis, and raw cordyceps sinensis.
68GF Score
Get the complete analysis for SHSE:600381
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600381 has been successfully added to your 
